NEWS - April 26, 99
biz.yahoo.com
April 26, 3:00 pm Eastern Time
Company Press Release
Wasatch Pharmaceutical Skin Care Announcement: Eczema and Contact Dermatitis
MIDVALE, Utah--(BUSINESS WIRE)--April 26, 1999--Wasatch Pharmaceutical Inc. (OTC BB:WASP), in a series of announcements concerning skin care, is releasing its report on clinical studies regarding the treatment of Eczema and Contact Dermatitis. In studies conducted over a period of four years with over 200 patients, the results are indicated as follows:
ECZEMA -- Patients in this group ranged in ages from infants to adults in their seventies. Types of Eczema ranged from hand eczema to full body eczema. Symptoms of Eczema are characterized by extreme patches of dry skin, inflammation, itching, measles-like sores and open bleeding cracked skin. For all types of Eczema treated in this study, Wasatch realized an 85% success rate. Success is interpreted as total or near total eradication of this pervasive skin condition. This is a major achievement in the treatment of Eczema, and will allow Wasatch to make an important contribution to the eradication of this disease, especially in the suffering of children. It is estimated that 3-4% of the U.S. population is affected by this debilitating skin disease.
CONTACT DERMATITIS -- As with Eczema, this skin disease has been very elusive, with current treatments having little success. In studies conducted by Wasatch, the emphasis was on the eradication of the disease, and not just treating symptoms as with existing therapies. Symptoms of Contact Dermatitis are characterized by extreme inflammation of the skin, ulceration, measles-like sores and painful red patches on the skin. Like Eczema, this condition can affect any part of the body and patients of all ages. Success with Contact Dermatitis exceeded all expectations. Wasatch reports a 95% success rate, surpassing that of Eczema. It is estimated that 1-2% of the U.S. population is affected by this skin condition.
With this announcement, along with previous and future announcements, it is clear that Wasatch Pharmaceutical Inc. has become a world leader in this discipline of medicine and will provide long awaited relief for serious skin diseases. Funds now being received by Wasatch will translate into strong marketing programs that will insure a long and profitable future from medical products that impact most of these serious skin disorders.
NOTE: Any statements released by Wasatch Pharmaceutical Inc. that are not strictly historical are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Editors and investors are cautioned that forward-looking statements invoke risk and uncertainties that may affect the company's business prospects and performance. These include economic, competitive, governmental, technological and other factors discussed in the company's filings with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Contact:
Wasatch Pharmaceutical Inc., Midvale
Gary Heesch, 801/272-1709
-------------------------------------------------------------------------------- |
